medigraphic.com
ISSN 1561-3119 (Electronic)

2022, Number 2

<< Back Next >>

Rev Cubana Pediatr 2022; 94 (2)

Infection disseminated by the vaccine bacillus Calmette-Guerin

Abreu SG, González VJA, Fuentes FG, Portuondo LR

Language: Spanish
References: 34
Page: 1-14
PDF size: 508.22 Kb.


ABSTRACT

Introduction: The infection disseminated by the vaccine bacillus Calmette-Guerin is a rare severe adverse reaction associated with immunodeficiency.
Objective: Describe a series of five cases with disseminated vaccine infection.
Presentation of cases: : There are five cases vaccinated at birth: predominance of the male sex in 4 (80%), average age onset: 8.4 months in 2 (15 %) and age at diagnosis: 17.8 months in 6 (31 %); clinical picture of ulcerated vaccine footprint, ipsilateral axillary lymphadenitis and in distal regions, hepatosplenomegaly, involvement of other organs, with systemic and nutritional manifestations. There was consanguinity in three of the patients and suspicious family history of immunodeficiency in three others. All died: three were sick before the age of 3. Conventional immunological studies were performed in all cases. One patient had severe combined immunodeficiency, chronic granulomatous disease was suspected in one, and Mendelian susceptibility syndrome to mycobacteria in three.
Conclusions: Although the BCG vaccine rarely presents dissemination of the vaccine bacillus, this entity should be suspected in young children, with the severe and systemic characteristics described, with manifestations suggestive to tuberculosis that do not respond to first-line anti-tuberculous treatment.


REFERENCES

  1. Arts RJW, Carvalho A, La Rocca C, Palma C, Rodrigues F, Silvestre R, et al. Immunometabolic Pathways in BCG-Induced Trained Immunity Cell Reports. 2016;17:2562-71. DOI: http://dx.doi.org/10.1016/j.celrep.2016.11.0111.

  2. Pöyhönen L, Bustamante J, Casanova JL. Life-Threatening Infections Due to Live-Attenuated Vaccines: Early Manifestations of Inborn Errors of Immunity. J Clin Immunol. 2019;39:376-90. DOI: https://doi.org/10.1007/s10875-019-00642-32.

  3. Principi N, Esposito S. The present and future of tuberculosis vaccinations. Tuberculosis. 2015;95:6e13. DOI: http://dx.doi.org/10.1016/j.tube.2014.10.0043.

  4. Villena-Martínez R. BCG 1948-: ¿La Misma Cepa? Neumol Pediatr. 2015 [acceso 15/08/2021];10(4):189-93. Disponible en: Disponible en: https://www.neumologia-pediatrica.cl/PDF/2015104/BCG-1948.pdf 4.

  5. Adinarayanan S, Culp RK, Subramani R, Abbas KM, Radhakrishna S, Swaminathan S. Role of bacilli Calmette-Guérin in preventing tuberculous. Infection. Int J Tuberc Lung Dis. 2017;21(4):420-4. DOI: http://dx.doi.org/10.5588/ijtld.16.08335.

  6. Apagüeño-Ruiz C, Peceros-Escalante J, Pomar-Morante R, Véliz-Lazo B, Ballona-Chambergo R. Infección diseminada por Bacilo Calmette-Guérin en un lactante con inmunodeficiencia: reporte de caso. Rev Peru Med Exp Salud Publica. 2019;36(1):134-7. DOI: 10.17843/rpmesp.2019.361.3666

  7. Venkataraman A, Yusuff M, Liebeschuetz S, Riddell A, Prendergast AJ. Management and outcome of Bacille Calmette-Guérin vaccine adverse reactions. Vaccine. 2015;33(41):5470-4. DOI: doi:10.1016/j.vaccine.2015.07.1037.

  8. Rermruay R, Rungmaitree S, Chatpornvorarux S, Brukesawan C, Wittawatmongkol O, Lapphra K, et al. Clinical features and outcomes of Bacille Calmette-Guérin (BCG)-induced diseases following neonatal BCG Tokyo-172 strain immunization. Vaccine. 2018;36(28):4046-53. DOI: 10.1016/j.vaccine.2018.05.098

  9. Bolursaz MR, Lotfian F, Velayati AA. Bacillus Calmette-Guérin vaccine complications in Iranian children at a University Hospital. Allergol immunopathol. 2017 [acceso 20/07/2021];45(4):356-61. Disponible en: Disponible en: https://scholar.google.com/scholar_lookup?title=Bacillus%20Calmette-Guerin%20vaccine%20complications%20in%20Iranian%20children%20at%20a%20university%20hospital&journal=Allergol%20Immunopathol%20%28Madr%29&volume=45&issue=4&pages=356-361&publication_year=2017&author=Bolursaz%2CMR&author=Lotfian%2CF&author=Velayati%2CAAElsevier 9.

  10. Alyasin S, Abolnezhadian F, Khoshkhui M. A Case of Probable MHC Class II Deficiency with Disseminated BCGitis. Iran J Immunol. 2015 [acceso 15/08/2021];12(3):219-25. Disponible en: Disponible en: https://www.pubmed.ncbi.nlm.nih.gov/26412640/ 10.

  11. Quero-Hernández A, Velasco-Santiago MM, Reyes-Gómez U, Reyes-Hernández KL, Quero-Estrada A. BCGosis y Enfermedad Granulomatosa Crónica. Reporte de caso clínico. Bol Clin Hosp Infant Edo Son. 2018 [acceso 04/07/2021];35(2);124-31. Disponible en: Disponible en: https://www.medigraphic.com/pdfs/bolclinhosinfson/bis-2018/bis182j.pdf&ved=2ahUKEwj5jfSCovDyAhWDZzABHUjEA5oQFnoECAoQAg&usg=AOvVaw38YkSGGLko4nuppK1EM6Cg 11.

  12. Lu S, Li T, Xi X, Chen Q, Liu X. Clinical and laboratory observation of Bacillus Calmette-Guérin infections. Int J Clin Exp Med. 2015 [acceso 04/07/2021];8(6):10099-104. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538067/ 12.

  13. Mohapatra S, Sethy S, Mohanty P, Mohapatra A, Pradhan S. Primary paediatric TH1 immunodeficiency with BCG-osis. Internat J Case Reports Images. 2012;3(5):36-40.

  14. Casanova JL, Blanche S, Emile JF, Jouanguy E, Lamhamedi S, Altare F, et al. Idiopathic Disseminated Bacillus Calmette-Guérin Infection: A French National Retrospective Study. Pediatrics.1996;98(4):774-8.

  15. Pourakbari B, Sadeghi RH, Mahmoudi S, Parvaneh N, Keshavarz S, Mamishia S. Evaluation of interleukin-12 receptor β1 and interferon gamma receptor 1 deficiency in patients with disseminated BCG infection. Allergol Immunopathol (Madr). 2019;47(1):38-42. DOI: https://doi.org/10.1016/j.aller.2018.06.00515.

  16. Hesseling AC, Cotton MF, Fordham von Reyn C, Graham SM, Gie RP, Hussey GD. Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. Int J Tuberc Lung Dis. 2008;12(12):1376-9.

  17. Mahmoudi S, Khaheshi S, Pourakbari B, Aghamohammadi A, Valian SP, Bahador S, et al. Adverse reactions to Mycobacterium bovis bacille Calmette-Guérin vaccination against tuberculosis in Iranian children. Clin Exp Vaccine Res. 2015;4(2):195-9. DOI: 10.7774/cevr.2015.4.2.195

  18. Ratnatunga CN, Lutzky VP, Kupz A, Doolan DL, Reid DW, Field M, et al. The Rise of Non-Tuberculosis Mycobacterial Lung Disease. Front Immunol. 2020;11:303. DOI: 10.3389/fimmu.2020.00303

  19. Taur PD, Gowri V, Pandrowala AA, Iyengar VV, Chougule A, Golwala Z, et al. Clinical and Molecular Findings in Mendelian Susceptibility to Mycobacterial Diseases: Experience From India. Front Immunol. 2021;12:631298. DOI: https://doi.org/10.3389/fimmu.2021.63129819.

  20. Bustamante J. Mendelian susceptibility to mycobacterial disease: recent discoveries. Hum Genet. 2020;139(6-7):993-1000. DOI: 10.1007/s00439-020-02120-y20.

  21. Nekooie-Marnany N, Deswarte C, Ostadi V, Bagherpour B, Taleby E, Hakemi EG, et al. Impaired IL-12- and IL-23-Mediated Immunity due to IL-12Rβ1 deficiency in Iranian Patients with Mendelian Susceptibility to Mycobacterial Disease. Clin Immunol. 2018;38(7):787-93. DOI: 10.1007/s10875-018-0548-1

  22. Indumathi CK, Kowta PM, Poornima RN, Lewin S. Clinical Profile and Outcome of Clinical BCG Disease in Infants. Indian Pediatr. 2014;51:730-2.

  23. Esteve-Sole A, Sánchez-Dávila SP, Deyà-Martínez A, Freeman AF, Zelazny AM, Dekker JP, et al. Severe BCG-osis Misdiagnosed as Multidrug-Resistant Tuberculosis in an IL-12Rβ1-Deficient Peruvian Girl. J Clin Immunol. 2018;38:712-716. DOI: 10.1007/s10875-018-0535-6

  24. Hernández-Ramos E, Marsán-Suárez V. Enfermedad granulomatosa crónica: fisiopatología genética y molecular. Pruebas diagnósticas vigentes. Rev. cubana hematol. inmunol. hemoter. 2021 [acceso 17/09/2021];37(2):e1297 Disponible en: Disponible en: https://www.revhematologia.sld.cu/index.php/hih/article/view/1297/1122 24.

  25. Ministerio de Salud Pública. Anuarios Estadísticos de Salud. La Habana: Minsap, Dirección Nacional de Registros Médicos y Estadísticas de Salud; 2020 [acceso 17/08/2021]. Disponible en: Disponible en: http://www.sld.cu/sitios/dne 25.

  26. Abreu-Suárez G, González-Valdés JA, González-Ochoa E, Suárez-Álvarez L. The Challenge of Eliminating Childhood Tuberculosis in Cuba. MEDICC Review. 2019;21(4):59-63. DOI: https://doi.org/10.37757/MR2019.V21.N4.1026.

  27. Al-Waili B, Al-Mufarajii N, Al-Hashmi S, Al-Ajmi A, Al-Sukaiti A. Bacillus Calmette-Guérin vaccine-related complications in children in Oman. Ann Saudi Med. 2021;41(1):24-30. DOI: 10.5144/0256-4947.2021.24

  28. Ying W, Sun J, Liu D, Hui X, Yu Y, Wang J, et al. Clinical Characteristics and Immunogenetics of BCGosis/BCGitis in Chinese Children: A 6 Year Follow-Up Study. PLoS ONE. 2014;9(4):e94485. DOI: 10.1371/journal.pone.0094485

  29. Zhou Q, Hui X, Ying W, Hou J, Wang W, Liu D, et al. A Cohort of 169 Chronic Granulomatous Disease Patients Exposed to BCG Vaccination: a Retrospective Study from a Single Center in Shanghai, China (2004-2017). J Clin Immunol. 2018;38(3):260-272. DOI: 10.1007/s10875-018-0486-y

  30. Ong RYL, Chan SWB, Chew SJ, Liew WK, Thoon KC, Chong CY, et al. Disseminated Bacillus-Calmette-Guérin Infections and Primary Immunodeficiency Disorders in Singapore: A Single Center 15-Year Retrospective Review. Int J Inf Dis. 2020;97:117-25. DOI: 10.1016/j.ijid.2020.05.117

  31. Chinn IK, Orange JS. Immunodeficiency Disorders. Pediatr Rev. 2019;40(5):229-42. DOI: 10.1542/pir.2017-0308

  32. Al‑Hammadi S, Alsuwaidi AR, Alshamsi ET, Ghatasheh GA, Souid AK. Disseminated Bacillus Calmette‑Guérin (BCG) infections in infants with immunodeficiency. BMC Res Notes. 2017;10:177. DOI: 10.1186/s13104-017-2499-7

  33. Boisson-Dupuis S, Bustamante J. Mycobacterial diseases in patients with inborn errors of immunity. Curr Op Inmunol. 2021;72:262-71. DOI: 10.1016/j.coi.2021.07.001

  34. World Health Organization. BCG vaccine: WHO position paper, February 2018-recommendations. Vaccine. 2018;36:-10. DOI: 10.1016/j.vaccine.2018.03.009




2020     |     www.medigraphic.com